A dermatologist or a consultation through Doctronic.ai can help distinguish this rash from similar-looking conditions before you start treatment
This efficacy in PIONEER 8 was long-lasting and seen at week 52 [ETD 3.5 kg, 95% CI 4.5 to 2.6 (7 mg), 4.9 kg, 95% CI 5.9 to 3.9 (14 mg)
PubMed Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition Supports body-composition, lean-mass, and metabolic-risk context
Serious adverse effects are rare in clinical trials
m hot ng chuyn ha Ch n ny tiu hao calo, mc tiu ca bn nn l gi li cng nhiu calo cng tt
The SURPASS trial series (SURPASS 1-5) and SURMOUNT series provide granular data across diverse populations including patients with cardiovascular disease, chronic kidney disease, and diabetes making Tirzepatide the more data-rich compound for translational research applications